Remove trial restrictions Start for $1

Serving leading biopharmaceutical companies globally:

Medtronic
Express Scripts
McKesson
Merck
Boehringer Ingelheim
Baxter

Last Updated: May 17, 2022

CLINICAL TRIALS PROFILE FOR NASONEX


✉ Email this page to a colleague

« Back to Dashboard

505(b)(2) Clinical Trials for Nasonex

This table shows clinical trials for potential 505(b)(2) applications. See the next table for all clinical trials
Trial Type Trial ID Title Status Sponsor Phase Start Date Summary
New Formulation NCT00779740 ↗ Equivalency Study of Two Formulations of Mometasone Furoate Nasal Spray (Study P04419) Completed Merck Sharp & Dohme Corp. Phase 3 2005-02-01 This is a multicenter, open-label, randomized, parallel group comparison study to verify the clinical equivalency of the old formulation (50 mcg as mometasone furoate [MF] in 50 μL of solution per spray) to the new formulation (50 mcg as MF in 100 μL of solution per spray) in patients with perennial allergic rhinitis.
>Trial Type >Trial ID >Title >Status >Phase >Start Date >Summary

All Clinical Trials for Nasonex

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00070707 ↗ Nasonex Compared With Placebo in Participants With Seasonal Allergic Rhinitis (SAR) and Concomitant Asthma (P03280) Completed Integrated Therapeutics Group Phase 4 2003-04-03 This study will compare mometasone nasal spray to placebo in treating the nasal and asthma symptoms experienced by participants with seasonal allergic rhinitis (SAR) and concomitant asthma.
NCT00070707 ↗ Nasonex Compared With Placebo in Participants With Seasonal Allergic Rhinitis (SAR) and Concomitant Asthma (P03280) Completed Merck Sharp & Dohme Corp. Phase 4 2003-04-03 This study will compare mometasone nasal spray to placebo in treating the nasal and asthma symptoms experienced by participants with seasonal allergic rhinitis (SAR) and concomitant asthma.
NCT00117611 ↗ Xolair in Patients With Chronic Sinusitis Completed Genentech, Inc. Phase 4 2005-07-01 The purpose of this study is to determine if treatment with the anti-IgE antibody, Xolair (omalizumab), will improve objective and subjective evidence of chronic sinusitis.
NCT00117611 ↗ Xolair in Patients With Chronic Sinusitis Completed Novartis Pharmaceuticals Phase 4 2005-07-01 The purpose of this study is to determine if treatment with the anti-IgE antibody, Xolair (omalizumab), will improve objective and subjective evidence of chronic sinusitis.
NCT00117611 ↗ Xolair in Patients With Chronic Sinusitis Completed University of Chicago Phase 4 2005-07-01 The purpose of this study is to determine if treatment with the anti-IgE antibody, Xolair (omalizumab), will improve objective and subjective evidence of chronic sinusitis.
NCT00224523 ↗ Long Term Safety Of GW685698X Via Nasal Biopsy Completed GlaxoSmithKline Phase 3 2005-09-01 Long term safety (52 weeks) of GW685698X on the nasal mucosa via nasal biopsy with an active control group (Nasonex®) and a healthy volunteers control group in subjects 18 years old with perennial allergic rhinitis . Allergic rhinitis is an inflammatory disorder of the upper airway that occurs following allergen exposure. Perennial allergic rhinitis is triggered by house dust mites, animal dander, etc., possibly causing symptoms year-round including nasal congestion, rhinorrhea and/or nasal itching.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Nasonex

Condition Name

Condition Name for Nasonex
Intervention Trials
Allergic Rhinitis 10
Seasonal Allergic Rhinitis 10
Rhinitis, Allergic, Perennial 6
Rhinitis 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Nasonex
Intervention Trials
Rhinitis 40
Rhinitis, Allergic 36
Rhinitis, Allergic, Seasonal 17
Rhinitis, Allergic, Perennial 11
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Nasonex

Trials by Country

Trials by Country for Nasonex
Location Trials
United States 119
China 5
Canada 5
Sweden 2
Belgium 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Nasonex
Location Trials
Texas 8
Illinois 7
North Carolina 5
New York 5
Missouri 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Nasonex

Clinical Trial Phase

Clinical Trial Phase for Nasonex
Clinical Trial Phase Trials
Phase 4 20
Phase 3 29
Phase 2 4
[disabled in preview] 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Nasonex
Clinical Trial Phase Trials
Completed 44
Terminated 6
Withdrawn 4
[disabled in preview] 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Nasonex

Sponsor Name

Sponsor Name for Nasonex
Sponsor Trials
Merck Sharp & Dohme Corp. 29
University of Chicago 3
Schering-Plough 3
[disabled in preview] 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Nasonex
Sponsor Trials
Industry 58
Other 19
NIH 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
Boehringer Ingelheim
Express Scripts
Colorcon
McKesson
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.